Apellis Pharmaceuticals (APLS) PT Lowered to $82 at BofA Securities
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $82.00 (from $84.00) while maintaining a Buy rating.
You May Also Be Interested In
- Stella International Holdings (1836:HK) (SLNLF) PT Lowered to HK$10 at Macquarie
- Alibaba (9988:HK) (BABA) PT Raised to HK$188.70 at Macquarie
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
